VistaGen Therapeutics, Inc. Uncategorized Contracts & Agreements
20 Contracts & Agreements
- Exclusive Negotiation Agreement by and between Fuji Pharma Co., Ltd. and Vistagen Therapeutics, Inc., dated September 1, 2023 (Filed With SEC on September 8, 2023)
- Open Market Sale AgreementSM, dated May 14, 2021, by and between VistaGen Therapeutics, Inc. and Jefferies LLC (Filed With SEC on May 14, 2021)
- Option Agreement, by and between VistaGen Therapeutics, Inc. and Pherin Pharmaceuticals, Inc., dated September 11, 2018 (Filed With SEC on September 13, 2018)
- EXCLUSIVE LICENSEAND SUBLICENSE AGREEMENT by andbetween VISTAGENTHERAPEUTICS, INC. and APOLLOBIOLOGICS LP EXCLUSIVE LICENSEAND SUBLICENSE AGREEMENT (Filed With SEC on February 13, 2017)
- R E C I T A L S : (Filed With SEC on November 14, 2016)
- VistaGen Therapeutics, Inc. (Filed With SEC on May 16, 2016)
- AGREEMENT (Filed With SEC on May 13, 2015)
- ACKNOWLEDGEMENT AND AGREEMENT (Filed With SEC on May 13, 2015)
- AMENDMENT NO. 2 (Filed With SEC on October 3, 2014)
- SUBSCRIPTIONAGREEMENT UNITS (Filed With SEC on June 25, 2014)
- VISTAGEN THERAPEUTICS, INC. (Filed With SEC on April 8, 2014)
- ASSIGNMENTANDASSUMPTION AGREEMENT (Filed With SEC on July 18, 2013)
- NEGATIVE COVENANT AGREEMENT (Filed With SEC on October 16, 2012)
- Notice of Award (Filed With SEC on December 20, 2011)
- SIGN AND RETURN THIS PAGE TO CIRMRT1-01012-1 NOTICE OF GRANT AWARD CIRM RFA-08-02:Tools & Technologies California Institute for Regenerative Medicine (Filed With SEC on December 20, 2011)
- VISTAGEN THERAPEUTICS, INC. (Filed With SEC on May 16, 2011)
- WITNESSETH: (Filed With SEC on May 16, 2011)
- Shawn K. Singh, JD Chief Executive Officer VistaGen Therapeutics, Inc. 384 Oyster Point Blvd., No. 8 South San Francisco, CA 94080 (650) 244-9997 ext. 224 ssingh@vistagen.com (Filed With SEC on May 16, 2011)
- CLINICAL STUDY AGREEMENT IND 75,807 AV-101 (Filed With SEC on May 16, 2011)
- VISTAGEN THERAPEUTICS, INC. CONVERSION AGREEMENT (Filed With SEC on May 16, 2011)